2MYG

Solution structure of the dithiolic glutaredoxin 2-C-Grx1 from the pathogen Trypanosoma brucei brucei

SOLUTION NMR

NMR Experiment
Experiment	Type	Sample Contents	Solvent	Ionic Strength	pH	Pressure	Temperature (K)	Spectrometer
1	3D HNCACB	50 mM sodium phosphate-1, 150 mM sodium chloride-2, 10 mM DTT-3, 1 mM EDTA-4, 0.05 % sodium azide-5, 0.2 mM PMSF-6, 1 mM [U-13C; U-15N] Tb 2-C-Grx1-7	95% H2O/5% D2O		7.2	ambient atm	298
2	3D HNCO	50 mM sodium phosphate-1, 150 mM sodium chloride-2, 10 mM DTT-3, 1 mM EDTA-4, 0.05 % sodium azide-5, 0.2 mM PMSF-6, 1 mM [U-13C; U-15N] Tb 2-C-Grx1-7	95% H2O/5% D2O		7.2	ambient atm	298
3	3DHN(CA)CO	50 mM sodium phosphate-1, 150 mM sodium chloride-2, 10 mM DTT-3, 1 mM EDTA-4, 0.05 % sodium azide-5, 0.2 mM PMSF-6, 1 mM [U-13C; U-15N] Tb 2-C-Grx1-7	95% H2O/5% D2O		7.2	ambient atm	298
4	3D CBCA(CO)NH	50 mM sodium phosphate-1, 150 mM sodium chloride-2, 10 mM DTT-3, 1 mM EDTA-4, 0.05 % sodium azide-5, 0.2 mM PMSF-6, 1 mM [U-13C; U-15N] Tb 2-C-Grx1-7	95% H2O/5% D2O		7.2	ambient atm	298
5	3D HBHA(CO)NH	50 mM sodium phosphate-1, 150 mM sodium chloride-2, 10 mM DTT-3, 1 mM EDTA-4, 0.05 % sodium azide-5, 0.2 mM PMSF-6, 1 mM [U-13C; U-15N] Tb 2-C-Grx1-7	95% H2O/5% D2O		7.2	ambient atm	298
6	3D HCCH-TOCSY	50 mM sodium phosphate-1, 150 mM sodium chloride-2, 10 mM DTT-3, 1 mM EDTA-4, 0.05 % sodium azide-5, 0.2 mM PMSF-6, 1 mM [U-13C; U-15N] Tb 2-C-Grx1-7	95% H2O/5% D2O		7.2	ambient atm	298
7	3D H(CCO)NH	50 mM sodium phosphate-1, 150 mM sodium chloride-2, 10 mM DTT-3, 1 mM EDTA-4, 0.05 % sodium azide-5, 0.2 mM PMSF-6, 1 mM [U-13C; U-15N] Tb 2-C-Grx1-7	95% H2O/5% D2O		7.2	ambient atm	298
8	3D H(CCO)NH	50 mM sodium phosphate-1, 150 mM sodium chloride-2, 10 mM DTT-3, 1 mM EDTA-4, 0.05 % sodium azide-5, 0.2 mM PMSF-6, 1 mM [U-13C; U-15N] Tb 2-C-Grx1-7	95% H2O/5% D2O		7.2	ambient atm	298
9	2D (H)CB(CGCC)H-TOCSY (PHE-OPTIMIZED)	50 mM sodium phosphate-1, 150 mM sodium chloride-2, 10 mM DTT-3, 1 mM EDTA-4, 0.05 % sodium azide-5, 0.2 mM PMSF-6, 1 mM [U-13C; U-15N] Tb 2-C-Grx1-7	95% H2O/5% D2O		7.2	ambient atm	298
10	2D (H)CB(CGCC)H-TOCSY (TYR-OPTIMIZED)	50 mM sodium phosphate-1, 150 mM sodium chloride-2, 10 mM DTT-3, 1 mM EDTA-4, 0.05 % sodium azide-5, 0.2 mM PMSF-6, 1 mM [U-13C; U-15N] Tb 2-C-Grx1-7	95% H2O/5% D2O		7.2	ambient atm	298
11	2D (H)CB(CGCC)H-TOCSY (HIS-OPTIMIZED)	50 mM sodium phosphate-1, 150 mM sodium chloride-2, 10 mM DTT-3, 1 mM EDTA-4, 0.05 % sodium azide-5, 0.2 mM PMSF-6, 1 mM [U-13C; U-15N] Tb 2-C-Grx1-7	95% H2O/5% D2O		7.2	ambient atm	298
12	3D 1H-13C NOESY aliphatic	50 mM sodium phosphate-1, 150 mM sodium chloride-2, 10 mM DTT-3, 1 mM EDTA-4, 0.05 % sodium azide-5, 0.2 mM PMSF-6, 1 mM [U-13C; U-15N] Tb 2-C-Grx1-7	95% H2O/5% D2O		7.2	ambient atm	298
13	3D 1H-13C NOESY aromatic	50 mM sodium phosphate-1, 150 mM sodium chloride-2, 10 mM DTT-3, 1 mM EDTA-4, 0.05 % sodium azide-5, 0.2 mM PMSF-6, 1 mM [U-13C; U-15N] Tb 2-C-Grx1-7	95% H2O/5% D2O		7.2	ambient atm	298
14	3D 1H-15N NOESY	50 mM sodium phosphate-1, 150 mM sodium chloride-2, 10 mM DTT-3, 1 mM EDTA-4, 0.05 % sodium azide-5, 0.2 mM PMSF-6, 1 mM [U-13C; U-15N] Tb 2-C-Grx1-7	95% H2O/5% D2O		7.2	ambient atm	298

NMR Spectrometer Information
Spectrometer	Manufacturer	Model	Field Strength
1	Bruker	AVANCE	900
2	Bruker	AVANCE	800
3	Bruker	AVANCE	500

NMR Refinement
Method	Details	Software
molecular dynamics	restrained Molecular Dynamics using AMPS-NMR server	TopSpin

NMR Ensemble Information
Conformer Selection Criteria	structures with the least restraint violations
Conformers Calculated Total Number	100
Conformers Submitted Total Number	20
Representative Model	1 (lowest energy)

Computation: NMR Software
#	Classification	Version	Software Name	Author
1	collection	TopSpin		Bruker Biospin
2	chemical shift assignment	CARA		Keller and Wuthrich
3	peak picking	UNIO'10		Torsten Herrmann
4	noesy assignment	UNIO'10		Torsten Herrmann
5	structure solution	CYANA	2.1	Guntert, Mumenthaler and Wuthrich
6	refinement	Amber		Case, Darden, Cheatham, III, Simmerling, Wang, Duke, Luo, ... and Kollman
7	refinement	X-PLOR NIH		Schwieters, Kuszewski, Tjandra and Clore

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM133198.